A similarly designed study and its results was presented by Lai et al.; it evaluated the PD-L1 expression level and tumour mutation burden in HER2-mutant NSCLC patients with respect to their response to immunotherapy [30]. This evidence concerns the gene ERBB2 and neoplasm.